A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer… - Blood, The Journal …, 2019 - ashpublications.org
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
[HTML][HTML] A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - ncbi.nlm.nih.gov
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
[引用][C] A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - BLOOD, 2019 - qmro.qmul.ac.uk
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with
sickle cell disease Toggle navigation Login Toggle navigation A phase 1/2 ascending dose …
sickle cell disease Toggle navigation Login Toggle navigation A phase 1/2 ascending dose …
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - europepmc.org
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - …, 2019 - pubmed.ncbi.nlm.nih.gov
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - kclpure.kcl.ac.uk
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> New treatments directly targeting
polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of …
polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of …
[HTML][HTML] A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - Elsevier
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - discovery.ucl.ac.uk
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
J Howard, CJ Hemmaway, P Telfer, DM Layton… - Blood, 2019 - europepmc.org
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …